Camargo Pharmaceutical Services announces Rick Bell as leader of Camargo's business development efforts. Bell joins Camargo after serving as the president and director of business development for ClinData Services Inc. in Bloomington, Indiana. Bell's past employment includes: site director and director of business development for Provident Clinical Research & Consulting Inc., and sales engineer for both Delta Power Systems Inc. and Powerscan Power Systems, Inc. Bell's responsibilities at Camargo will be continued relationships with current clients, follow up with prospective clients, identifying leads and helping educate the industry primarily on 505(b)(2) as well as the end-to-end drug development program Camargo offers as a service . "Camargo is an outstanding company," said Bell. "Joining Camargo's team will allow me to use my strengths to facilitate the continued growth of the company,"
Ken Phelps, President and CEO of Camargo views Bell as a benefit as well. "Rick is going to do great things for Camargo and its clients," said Phelps. "I am pleased to have such a talented individual join our staff."
Camargo Pharmaceutical Services offers scientific and regulatory drug development services for mid-sized pharmaceutical, biotechnology and drug delivery companies. With more than 150 FDA approvals, Camargo works with companies to develop comprehensive programs, managing every facet of the plan from formulation and testing the drug product, conducting clinical studies, and FDA application submissions. The chief scientific officer has also served as a team leader and reviewer in the new drug division of the U.S. Food and Drug Administration (FDA).
About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services focuses on strategic drug development program design and implementation, from end-to-end or at any intermediate stage. The services include pre-clinical feasibility assessments, CMC and CMO services, clinical program development, pharmacokinetics, CRO services, Phase I through IV studies and clinical trials, and regulatory review and submission via eCTD of INDs, NDAs, ANDAs, and 505(b)(2)s. Tel: 888-451-5708 or www.camargopharma.com.
Source: Camargo Pharmaceutical Services